NetworkNewsBreaks – aTyr Pharma, Inc.’s (NASDAQ: LIFE) Resolaris™ Granted Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy; Shares Higher
Shares of aTyr Pharma (NASDAQ: LIFE) are up more than 15% after the company said its lead product candidate, Resolaris™, received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy (LGMD) patients. Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells and is being developed as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, such as LGMD. Being granted Orphan Drug Designation by the FDA will advance the development of Resolaris and create opportunity for incentives under the program.…







